Bio-Rad Files New Lawsuit Against 10X Genomics for Patent Infringement
September 11 2019 - 5:48PM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
of life science research and clinical diagnostic products, today
announced that it has filed a patent infringement suit against 10X
Genomics, Inc. in the United States District Court for the District
of Delaware.
In the lawsuit Bio-Rad asserts that 10X Genomics infringes U.S.
Patent No. 8,871,444, which is exclusively licensed to Bio-Rad from
Harvard University and the Medical Research Council. This patent
covers techniques for detecting enzymatic reactions in microfluidic
droplets and is part of Bio-Rad's comprehensive portfolio of
droplet intellectual property. The suit asserts that 10X Genomics
infringes through the sale of its recently-announced Next GEM
family of products. As stated in Bio-Rad's Complaint, Harvard
University is joined in the case as a nominal defendant solely for
the legal purposes of jurisdiction and standing. Bio-Rad is seeking
all available remedies against 10X Genomics, including damages and
injunctive relief.
The suit filed today is Bio-Rad’s third action against 10X
Genomics in Delaware District Court and its second action that is
directed to 10X’s Next GEM products. In November 2018, a Delaware
jury found that 10X Genomics infringed patents licensed to Bio-Rad
by the University of Chicago and awarded damages of $23.9M. In
August 2019, the Delaware Court awarded Bio-Rad an additional $10.5
M in supplemental damages and interest and entered a permanent
injunction against 10X Genomics.
“Bio-Rad will continue to grow and protect its portfolio of
patents in the droplet microfluidics space that deliver
differentiated genomics technologies and enable world class
research,” said Norman Schwartz, Bio-Rad President and Chief
Executive Officer.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global
leader in developing, manufacturing, and marketing a broad range of
innovative products for the life science research and clinical
diagnostic markets. With a focus on quality and customer service
for over 65 years, our products advance the discovery process and
improve healthcare. Our customers are university and research
institutions, hospitals, public health and commercial laboratories,
biotechnology, pharmaceutical, as well as applied laboratories that
include food safety and environmental quality. Founded in 1952,
Bio-Rad is based in Hercules, California, and has a global network
of operations with more than 8,000 employees worldwide. Bio-Rad had
revenues exceeding $2.2 billion in 2018. For more information,
please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make that Bio-Rad will continue
to grow and protect its portfolio of patents in the droplet
microfluidics space that deliver differentiated genomics
technologies and enable world class research. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as “continue”, “will,” “expect,”
“anticipate,” “plan,” “intend,” “estimate,” “believe,” or similar
expressions or the negative of those terms or expressions, although
not all forward-looking statements contain these words. Such
statements involve risks and uncertainties, which could cause
actual results to vary materially from those expressed in or
indicated by the forward-looking statements. These risks and
uncertainties include risks relating to intellectual property
rights, international legal and regulatory risks, our ability to
develop and market new or improved products, our ability to compete
effectively, and product quality and liability issues. For further
information regarding our risks and uncertainties, please refer to
the “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operation” in Bio-Rad’s public
reports filed with the Securities and Exchange Commission,
including our most recent Annual Report on Form 10-K and our
Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place
undue reliance on forward-looking statements, which reflect an
analysis only and speak only as of the date hereof. We disclaim any
obligation to update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190911005787/en/
Bio-Rad Laboratories, Inc. Tina Cuccia, Corporate Communications
510-724-7000 tina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Sep 2023 to Sep 2024